title: The metabolic syndrome in HIV.
abstract: The metabolic syndrome (MS) is a term used to describe the clustering of risk factors for cardiovascular disease (CVD), including elevated triglyceride (TG), low high density lipoprotein cholesterol (HDL), hypertension, hyperglycemia/ insulin resistance and intra-abdominal obesity. This paper discusses why the prevalence of MS in the setting of HIV has been reported to range from 7-45% and how antiretroviral drugs might contribute to the development of MS. The MS has been reported to be a 'CVD risk enhancer', and much debate is ongoing on the independent risk of CVD associated with the MS. Based on a limited number of studies on MS in HIV with clinical end-points, there is no data to support that the MS is independently associated with an increased risk of CVD.
authors.affiliation: Copenhagen HIV Programme, University of Copenhagen, Faculty of Health Science, Blegdamsvej, Copenhagen N, Denmark. sww@cphiv.dk
authors.forename: Signe W
authors.initials: SW
authors.lastname: Worm
authors.forename: Jens D
authors.initials: JD
authors.lastname: Lundgren
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology; D005260:Female; D006678:HIV / Q000472:pathogenicity; D015658:HIV Infections / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D015994:Incidence; D008297:Male; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology; D015995:Prevalence; D012307:Risk Factors; D012737:Sex Factors
chemical_list: D019380:Anti-HIV Agents